Navigation Links
Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round
Date:2/24/2009

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised $7.1 million in a Series A financing co-led by InterWest Partners and Vivo Ventures. The two firms were instrumental in the formation of the company and recruitment of its team and are represented on the board of directors by general partners Nina Kjellson and Dr. Edgar Engelman, respectively. The funding will advance the company's lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.

Eiger is led by President and Chief Executive Officer David Cory, RPh, MBA, whose background spans over 20 years in large pharma, biotechnology, and specialty pharma with an established track record of commercial success, financial transactions, business development, and management experience. "We believe that disrupting the normal function of NS4B and NS5A proteins will lead to uniquely effective hepatitis C treatments," said David Cory, President and CEO of Eiger. "Our mission is to advance these novel small molecules into the clinic rapidly for the benefit of patients."

Eiger was founded on research conducted by Stanford professor Jeffrey Glenn, MD, PhD, whose recent research focuses on specific regions of HCV proteins NS4B and NS5A required for viral replication. "The unmet medical need in HCV treatment is significant," said Dr. Glenn. "Developing small molecule drugs and drug combinations against new HCV targets could change the HCV treatment paradigm and combat the emergence of drug resistance to new HCV polymerase and protease inhibitors." Dr. Glenn is Associate Professor of Medicine, Gastroenterology & Hepatology, Stanford University and Director of the Center for Hepatitis and Liver Tissue Engineering; he will serve as a consultant, scientific advisor and director to the company.

About InterWest Partners

InterWest Partners (http://www.interwest.com), founded in 1979, is a leading diversified venture capital firm focused on building long-term relationships with entrepreneurs and portfolio companies. Currently investing its ninth fund, IW IX, a $600 million fund, InterWest has more than $2 billion of capital raised since inception. InterWest has 17 investing partners in Menlo Park.

About Vivo Ventures

Vivo Ventures (http://www.vivoventures.com) is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies. The Vivo portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.

About Eiger BioPharmaceuticals, Inc.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. http://www.eigerbio.com

     Contact:
     David Cory
     President and CEO, Eiger BioPharmaceuticals, Inc.
     415-254-7534
     dcory@eigerbio.com

'/>"/>
SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
3. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
4. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
5. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. XTL Biopharmaceuticals Implements Restructuring Plan
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):